Oral Proteins & Peptides Market Companies and Growth
- Novo Nordisk
- Eli Lilly
- Pfizer
- Chiesi
- Rani Therapeutics
- Biora Therapeutics
- Entera Bio
- Oramed Pharmaceutical
- Enteris BioPharma
- Lonza
- Catalent
- Thermo Fisher Scientific
- Evonik Health Care
- Adare Pharma Solutions
- BASF Pharma Solutions
- Ashland
- Roquette
- Hovione
- Zealand Pharma
- Protagonist Therapeutics
Market Growth
The global oral proteins & peptides market size is calculated at US$ 8.05 billion in 2024, grew to US$ 9.36 billion in 2025, and is projected to reach around US$ 36.35 billion by 2034. The market is expanding at a CAGR of 16.34% between 2025 and 2034.
Drifts in the Oral Proteins & Peptides Market
In the global market, a rise in demand for non-invasive drug delivery systems and the expansion of the biopharmaceutical sector are fueling developments in this area.
- In April 2025, Merck & Co.'s peptides secured a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.
- In March 2025, CordenPharma, a global Contract Development & Manufacturing Organization (CDMO), entered into a strategic partnership with Viking Therapeutics, Inc., a clinical-stage company, to integrate the supply of GLP-1 peptides, injectables, and oral formulations.
Market Value Chain Analysis
R&D
The oral proteins & peptides market encompasses peptide synthesis, genetic engineering, and drug delivery technologies to develop more effective and stable oral formulations.
Key Players: Novo Nordisk A/S, AbbVie Inc., and Pfizer Inc.
Formulation and Final Dosage Preparation
To enhance stability and membrane permeability, lipid-based nanocarriers such as oil-in-water nanoemulsions, self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, and micelles are used in respective formulations and final dosage preparation.
Key Players: CD Formulation, UPM Pharmaceuticals
Clinical Trials and Regulatory Approvals
Various ongoing clinical trials are involved in the enhancement of patient outcomes, coupled with regulatory guidelines for fast track and breakthrough therapy designation in the oral proteins & peptides market.
Key Players: Biocon Ltd., Sanofi, Chiasma, Inc., UNGC, Proxima Concepts Limited (Diabetology Ltd.), US FDA, EMA, ICH
Latest Announcements by Industry Leaders
- In February 2025, Oramed Pharmaceuticals Inc. announced a definitive agreement with OraTech Pharmaceuticals Inc. and Hefei Tianhui Biotech Co., Ltd. to expand the development and commercialization of Oramed's ORMD-0801 oral insulin and other POD™-based innovative oral drug delivery technologies. Nadav Kidron, Chief Executive Officer of Oramed, commented that this is an exciting approach to introduce Oramed's technology and clinical development expertise with HTIT's state-of-the-art manufacturing capabilities.
- In August 2024, BridGene Biosciences, Inc., announced an expansion to its strategic partnership and licensing agreement with Galapagos NV with emphasizing the discovery of a highly selective oral SMARCA2 small molecule proteolysis targeting chimera (PROTAC). Ping Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences, replied that this collaboration will boost the discovery of novel drugs targeting crucial and restricted oncology targets.
Recent Developments in the Oral Proteins & Peptides Market
- In April 2025, Sai Life Sciences, a Contract Research, Development, and Manufacturing Organisation (CRDMO), introduced a Peptide Research Center at its integrated R&D campus in Hyderabad.
- In March 2025, CordenPharma, a Germany-based end-to-end pharmaceutical services company, launched its €1 billion investment to accelerate its peptide development and manufacturing capabilities.
- In January 2025, Verdiva Bio, a new clinical-stage cardiometabolic company, launches with over $410m in Series A financing to advance oral GLP-1 and oral amylin therapies for weight loss and maintenance.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
